FDA Approves Bayer's Sunharbo as First Factor XIa Inhibitor, Cutting Recurrent Stroke 26% in a 12,327-Patient Trial
Asundexian, taken with antiplatelets, lowered ischemic stroke from 8.4% to 6.2% without a significant rise in major bleeding overall, but bleeding was higher in patients over 75 and in the first 90 days.

Key facts
- The US Food and Drug Administration approved Bayer's asundexian, sold as Sunharbo, on 9 November 2026 as the first factor XIa inhibitor cleared in the United States.[1][2]
- In the 12,327-patient OCEANIC-STROKE trial, ischemic stroke occurred in 6.2% of patients on asundexian versus 8.4% on placebo, a hazard ratio of 0.74 (95% CI 0.65 to 0.84).[1]
- ISTH major bleeding in OCEANIC-STROKE was 1.9% on asundexian versus 1.7% on placebo, a difference that was not statistically significant (P = .46).[1]
- Major bleeding was higher with Sunharbo in patients older than 75 (2.6 versus 1.7 per 100 patient-years) and in the first 90 days of treatment (4.5 versus 3.1 per 100 patient-years), according to Healio.[3]
- Bayer set a list price of $748.50 for a 30-day supply of Sunharbo and says the figure does not reflect what most plans or patients pay.[2]
- The full OCEANIC-STROKE results were published in the New England Journal of Medicine (doi:10.1056/NEJMoa2513880), and the trial was funded by Bayer.[3]
The US Food and Drug Administration approved Bayer's asundexian, sold as Sunharbo, on 9 November 2026 as the first factor XIa inhibitor cleared in the United States, NeurologyLive reported. The once-daily 50 mg tablet, taken with antiplatelet therapy, cut recurrent ischemic stroke by 26% in the phase 3 OCEANIC-STROKE trial of 12,327 patients, with no statistically significant rise in major bleeding.
The approval covers adults after a recent non-cardioembolic ischemic stroke or a high-risk transient ischemic attack (TIA). It does not cover atrial fibrillation, the setting in which many anticoagulants are used. According to TCTMD, Bayer set a list price of $748.50 for a 30-day supply and said that figure does not reflect what most plans or patients pay.
What did the OCEANIC-STROKE trial show?
OCEANIC-STROKE was a double-blind, placebo-controlled phase 3 trial. Patients were randomized within 72 hours of a qualifying event, 6,162 to asundexian and 6,165 to placebo, and all were also given planned single or dual antiplatelet therapy, NeurologyLive reported. Median treatment lasted 14.2 months.
Ischemic stroke, the primary endpoint, occurred in 6.2% of the asundexian group and 8.4% of the placebo group, a hazard ratio of 0.74 (95% confidence interval 0.65 to 0.84; P below .001). That is an absolute difference of 2.2 percentage points. The composite of cardiovascular death, heart attack or stroke came to 9.2% versus 11.1%, and the composite of death from any cause, heart attack or stroke to 10.5% versus 12.3%, per the same report.
These are peer-reviewed results. Healio cites the full trial publication as Sharma M, et al., in the New England Journal of Medicine (doi:10.1056/NEJMoa2513880). The regulatory approval itself rests on that trial, and the efficacy figures above come from it rather than from a press release alone.
How safe is it compared with placebo?
Bleeding is the central question for any drug that interferes with clotting, and the headline safety finding is favourable. International Society on Thrombosis and Haemostasis (ISTH) major bleeding, the trial's primary safety endpoint, occurred in 1.9% of patients on asundexian and 1.7% on placebo (hazard ratio 1.10; 95% confidence interval 0.85 to 1.44; P = .46), according to NeurologyLive. The broader measure of major or clinically relevant non-major bleeding was 5.5% versus 5.0%, also not statistically significant. Adverse events were reported in 69.3% versus 70.1% of patients, and serious adverse events in 19.2% versus 19.5%.
The picture is less clean in subgroups. Healio reported that major bleeding was higher with Sunharbo in patients older than 75 (2.6 versus 1.7 per 100 patient-years) and during the first 90 days of treatment (4.5 versus 3.1 per 100 patient-years). Gastrointestinal bleeding occurred at 2.7 versus 2.1 per 100 patient-years, a hazard ratio of 1.3 with a confidence interval of 1 to 1.6. Bayer says about 74% of gastrointestinal bleeding events in the Sunharbo group were clinically relevant non-major or minor bleeds, as Healio relayed. The most common side effect was diarrhea, in 3.4% of Sunharbo patients versus 2.8% on placebo, according to TCTMD.
The label also carries cautions. Per NeurologyLive, the drug is not recommended in moderate or severe hepatic impairment, should be withheld at least 24 hours before elective surgery or invasive procedures and for at least 24 hours after thrombolysis for acute ischemic stroke, and should be avoided with combined P-glycoprotein and strong CYP3A4 inducers, which may reduce its effectiveness. TCTMD added that elevated liver enzymes were seen, with Bayer saying about three-quarters were mild.
Why does a new drug class matter for stroke care?
Factor XIa is a clotting protein. According to Healio, Bayer says Sunharbo reduces the amplification of thrombin generation, aiming to curb thrombosis with a smaller effect on normal clotting. The hypothesis behind the class is that harmful clots can be blunted without the bleeding penalty that standard anticoagulants carry.
Ashkan Shoamanesh, a co-principal investigator of the trial at McMaster University, told TCTMD that up to 20% of patients with non-cardioembolic ischemic stroke have a recurrent stroke within five years despite guideline-based care. He described the drug as offering protection "without the bleeding penalty that has historically limited more intensive antithrombotic treatment." NeurologyLive quoted him as saying that non-cardioembolic ischemic strokes account for about 45% of the 12 million strokes occurring globally each year.
Mike Sharma, lead investigator and senior scientist at the Population Health Research Institute, said in Healio that the drug "reduces recurrent stroke significantly more than antiplatelets alone," and that the effect begins early and continues as far as patients were followed. Healio noted that Sharma disclosed consulting for Bayer and other companies, and that Bayer funded OCEANIC-STROKE with payments to his institution. He also disclosed research funding for AXIOMATIC-SSP, a separate trial, from Bristol Myers Squibb and Janssen. Because the investigators' views are quoted alongside Bayer's financial relationship with them, readers should weigh their enthusiasm accordingly, though the underlying figures are from a peer-reviewed publication.
What happens next?
Bayer expects shipments to begin in mid-to-late November, Healio reported, and the drug is under review by the European Medicines Agency and Japan's Ministry of Health, Labour and Welfare. TCTMD reported that China has already approved it.
Uptake is the next test. Shoamanesh told TCTMD that initial inertia with new drug classes is common, citing unfamiliarity, safety questions, prescribing complexity and cost or reimbursement. Cheryl Bushnell of Wake Forest said cost is "probably going to be the main limiting factor." Bayer says some patients may be able to obtain the drug free through the Bayer US Patient Assistance Foundation.
For clinicians, the practical decision is how to weigh a 2.2 percentage-point absolute reduction in ischemic stroke against a bleeding profile that was neutral overall but less favourable in patients over 75 and in the first 90 days. For payers, the question is whether a roughly $750 monthly list price is justified for an add-on to antiplatelets.
What we don't know yet
Several points remain unsettled in the sources read. TCTMD reported that subanalyses suggested recurrent strokes were less severe, but those analyses are secondary. Real-world bleeding rates outside a trial population, are unknown. Whether benefit persists beyond the trial's median follow-up of 19 months is, according to Healio, something Bayer expects based on the drug's mechanism rather than on data. The price Bayer lists is not the price most patients will pay, and the net cost to health systems has not been reported.




